CA2584221A1 - Analogues de l'hormone adrenocorticotropique et procedes associes - Google Patents

Analogues de l'hormone adrenocorticotropique et procedes associes Download PDF

Info

Publication number
CA2584221A1
CA2584221A1 CA002584221A CA2584221A CA2584221A1 CA 2584221 A1 CA2584221 A1 CA 2584221A1 CA 002584221 A CA002584221 A CA 002584221A CA 2584221 A CA2584221 A CA 2584221A CA 2584221 A1 CA2584221 A1 CA 2584221A1
Authority
CA
Canada
Prior art keywords
acth
amino acid
acth analog
seq
corticosteroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002584221A
Other languages
English (en)
Inventor
Miles B. Brennan
Robert M. Dores
Carrie Haskell-Luevano
Ute H. Hochgeschwender
Jessica I. Costa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Denver
Oklahoma Medical Research Foundation
University of Florida
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2584221A1 publication Critical patent/CA2584221A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002584221A 2004-10-27 2005-10-27 Analogues de l'hormone adrenocorticotropique et procedes associes Abandoned CA2584221A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62243604P 2004-10-27 2004-10-27
US60/622,436 2004-10-27
PCT/US2005/038789 WO2006052468A2 (fr) 2004-10-27 2005-10-27 Analogues de l'hormone adrenocorticotropique et procedes associes

Publications (1)

Publication Number Publication Date
CA2584221A1 true CA2584221A1 (fr) 2006-05-18

Family

ID=36336951

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002584221A Abandoned CA2584221A1 (fr) 2004-10-27 2005-10-27 Analogues de l'hormone adrenocorticotropique et procedes associes

Country Status (13)

Country Link
US (4) US7264314B2 (fr)
EP (2) EP2446894A3 (fr)
JP (2) JP2008518026A (fr)
KR (3) KR101058467B1 (fr)
CN (2) CN101947310A (fr)
AU (2) AU2005305157B2 (fr)
CA (1) CA2584221A1 (fr)
IL (1) IL182818A0 (fr)
MX (1) MX2007004676A (fr)
NZ (1) NZ554559A (fr)
RU (2) RU2407751C2 (fr)
SG (1) SG156680A1 (fr)
WO (1) WO2006052468A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004676A (es) 2004-10-27 2007-11-14 Univ Denver Analogos de la hormona adrenocorticotropica y metodos relacionados.
WO2009040051A2 (fr) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
WO2014168721A2 (fr) 2013-04-12 2014-10-16 Tufts Medical Center Procédés et systèmes pour mettre au point et/ou caractériser des agents ligands lipidés solubles
CN104277105B (zh) * 2013-07-12 2017-12-12 国家纳米科学中心 抑制β淀粉样蛋白聚集和毒性的多肽抑制剂及其应用
CN103724427B (zh) * 2013-11-29 2016-09-28 青岛康原药业有限公司 一种精制促皮质素的方法
CN105899950B (zh) * 2013-12-19 2017-11-24 根特大学 鱼鳞中作为对于慢性应激的生物标记物的糖皮质激素的量化
EP3107569A4 (fr) * 2014-02-20 2018-02-21 Alder Biopharmaceuticals, Inc. Anticorps anti-acth et leur utilisation
EP4691556A3 (fr) * 2014-12-19 2026-04-29 H. Lundbeck A/S Anticorps anti-acth humanisés et leur utilisation
CN104530219A (zh) * 2014-12-23 2015-04-22 青岛康原药业有限公司 一种精制促皮质素的方法
US10899834B2 (en) 2015-04-16 2021-01-26 H. Lundbeck A/S Anti-PACAP antibodies
EP3405208B1 (fr) 2016-01-22 2020-04-29 Tufts Medical Center, Inc. Composés et procédés pour le traitement de l'inflammation
CN105669856A (zh) * 2016-02-13 2016-06-15 王大勇 一种基因重组长效人促肾上腺皮质激素及其制备方法
IL302705A (en) 2016-03-01 2023-07-01 Immatics Biotechnologies Gmbh Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer
KR102444717B1 (ko) 2016-04-15 2022-09-16 하. 룬드벡 아크티에셀스카브 인간화 항-pacap 항체 및 그의 용도
CN106478771A (zh) * 2016-10-09 2017-03-08 李世军 一种氨基酸神经四肽的合成方法
US11338018B2 (en) 2016-12-19 2022-05-24 Harrow Ip, Llc Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof
US20180169191A1 (en) * 2016-12-19 2018-06-21 Eton Pharmaceuticals, Inc. Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof
CN110698557B (zh) * 2019-11-06 2021-06-18 郑州伊美诺生物技术有限公司 Acth突变体、重组蛋白及其应用，以及含有该acth重组蛋白的试剂盒
US12433936B2 (en) 2021-04-12 2025-10-07 Nanjing Hanxin Pharmaceutical Technology Co., Ltd. High-purity adrenocorticotropic hormone analogue and a large-scale preparation method thereof
CN116761809A (zh) * 2021-04-12 2023-09-15 南京汉欣医药科技有限公司 一种高纯的人促肾上腺皮质激素或其类似物及其规模化制备方法
CN120420414A (zh) * 2024-02-04 2025-08-05 南京汉欣医药科技有限公司 含有人工合成的促皮质素类似物的组合物、其制备方法以及其用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
US4415546A (en) 1981-05-12 1983-11-15 Janakiraman Ramachandran Biologically active analogs of ACTH and radioimmuno assay therefor
US4457864A (en) 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
US4649191A (en) 1984-05-10 1987-03-10 Gibson-Stephens Neuropharmaceuticals, Inc. Conformationally constrained alpha-melanotropin analogs with specific central nervous system activity
ATE84420T1 (de) 1986-02-03 1993-01-15 University Patents Inc Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5049547A (en) 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
US4948580A (en) 1988-12-08 1990-08-14 E. R. Squibb & Sons, Inc. Muco-bioadhesive composition
JPH02258718A (ja) 1989-03-31 1990-10-19 Nippon Kayaku Co Ltd ペースト状基剤及び製剤
US5189018A (en) 1991-08-19 1993-02-23 Wayne State University Method for reduction of central nervous system (cns) edema resulting from head and spinal cord trauma
CA2150803C (fr) 1992-12-02 2006-01-31 Henry Auer Hormone de croissance a liberation controlee qui contient des microspheres
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
EP0681491B1 (fr) 1993-01-29 2000-12-13 Aradigm Corporation Apport intrapulmonaire d'hormones
US5554380A (en) 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
PT779806E (pt) 1994-09-09 2001-02-28 Takeda Chemical Industries Ltd Preparacao de libertacao sustentada contendo um sal metalico de um peptido
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
PT831787E (pt) 1995-06-07 2002-02-28 Alkermes Inc Composicao para libertacao sustentada da hormona de crescimento humano
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6346390B1 (en) * 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
GB9606016D0 (en) 1996-03-22 1996-05-22 Smithkline Beecham Plc Novel use
IE960308A1 (en) 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
MY118835A (en) 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
US6056954A (en) 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
CA2331388A1 (fr) 1998-06-26 2000-01-06 Michael Thomas Clark Procede ameliore pour preparer des bases de schiff produits d'addition d'amines avec des aldehyde o-hydroxy et compositions de substances a base de ces produits
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
CA2377369A1 (fr) 1999-06-04 2000-12-14 Merck & Co., Inc. Piperidines substituees en tant qu'agonistes du recepteur de melanocortine-4
IES990700A2 (en) 1999-08-18 2001-08-22 Kinerton Ltd Process to make a sustained release formulation
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
WO2001080830A2 (fr) 2000-04-21 2001-11-01 Advanced Research And Technology Institute, Inc. Methode et composition pharmacotherapeutique destinees aux troubles du systeme nerveux central
EP1322954A4 (fr) 2000-09-13 2005-08-03 Eleanor Roosevelt Inst Procede de traitement de la resistance a l'insuline dans l'obesite et le diabete
CA2427146A1 (fr) 2000-10-25 2002-07-18 Mayo Foundation For Medical Education And Research Conjugues de fixation au recepteur de transcobalamine utiles pour le traitement d'une proliferation cellulaire anormale
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
JP2007501071A (ja) 2003-08-04 2007-01-25 アルザ・コーポレーシヨン 経皮作用剤流率を向上させる方法および装置
WO2005044142A2 (fr) 2003-11-10 2005-05-19 Angiotech International Ag Dispositifs intravasculaires et agents d'induction de fibrose
US20050147581A1 (en) 2003-11-19 2005-07-07 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes having improved stability and therapeutic use of the same
MX2007004676A (es) 2004-10-27 2007-11-14 Univ Denver Analogos de la hormona adrenocorticotropica y metodos relacionados.

Also Published As

Publication number Publication date
KR20100102752A (ko) 2010-09-24
JP2008518026A (ja) 2008-05-29
US20100260681A1 (en) 2010-10-14
NZ554559A (en) 2010-05-28
MX2007004676A (es) 2007-11-14
AU2005305157B2 (en) 2011-09-01
JP2012067099A (ja) 2012-04-05
US20070197774A1 (en) 2007-08-23
CN101947310A (zh) 2011-01-19
CN101189022A (zh) 2008-05-28
EP2446894A2 (fr) 2012-05-02
SG156680A1 (en) 2009-11-26
WO2006052468A3 (fr) 2007-01-11
US20060128620A1 (en) 2006-06-15
WO2006052468A2 (fr) 2006-05-18
KR101058467B1 (ko) 2011-08-24
US20080207518A1 (en) 2008-08-28
KR20120050440A (ko) 2012-05-18
RU2407751C2 (ru) 2010-12-27
EP1814574A4 (fr) 2009-08-05
KR20070112761A (ko) 2007-11-27
RU2010135499A (ru) 2012-02-27
US7264314B2 (en) 2007-09-04
KR101150242B1 (ko) 2012-06-13
KR101242543B1 (ko) 2013-03-22
IL182818A0 (en) 2007-08-19
EP1814574A2 (fr) 2007-08-08
EP2446894A3 (fr) 2013-02-20
AU2005305157A1 (en) 2006-05-18
US7919577B2 (en) 2011-04-05
RU2007119580A (ru) 2008-12-10
CN101189022B (zh) 2012-02-29
AU2011201914A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
US20100260681A1 (en) Adrenocorticotropic hormone analogs and related methods
EP0309100B1 (fr) Emploi de l'amyline ou CGRP pour le traitement du diabète sucré
US5175145A (en) Treatment of diabetes mellitus with amylin agonists
US20040266688A1 (en) Methods for modulating endometrium
JP5582477B2 (ja) 非閉経女性における卵胞貯蔵を調節するのに意図した医薬を製造するのにソマトスタチン又はその同族体の１つの使用
WO2012112919A1 (fr) Inhibition du facteur issu du stroma et blocage de cxcr4
EP2397151B1 (fr) Traitement des complications vasculaires du diabète
HK1148194A (en) Adrenocorticotropic hormone analogs and related methods
CN120189521B (zh) 一种长链修饰的ghrh激动剂及其应用
US20130039934A1 (en) Treatment of ige-mediated disease
Madsen European Journal of Endocrinology (1998) 139 552–561 ISSN 0804-4643 Ipamorelin, the first selective growth hormone secretagogue
HK1000934B (en) Use of amylin or cgrp for the treatment of diabetes mellitus
JPH06293660A (ja) 腫瘍壊死因子阻害活性を有する新規ペプチド

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140617